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Bordetella pertussis is the bacterium responsible for pertussis, a disease commonly referred to as 
whooping cough. Recently, pertussis has made a resurgence in the U.S. despite high-vaccination 
coverage. Possible causes of the increased number of pertussis cases include genetic evolution 
of B. pertussis, increased awareness of the disease, better laboratory diagnostics, and the switch 
from a whole-cellular (wP) vaccine to an acellular vaccine (aP) in the 1990s. Fortunately, just 
as B. pertussis is evolving, so is the arsenal of technologies used to understand and combat 
this pathogenic bacterium. Whole genome sequencing is one technology that helps researchers 
better understand the evolution B. pertussis. This project included the isolation of genomic DNA 
and sequencing of two novel B. pertussis strains isolated from patients in Virginia. This project 
also utilized bioinformatics to analyze data obtained from genomes of twelve previously 
sequenced B. pertussis isolates. Specifically, the genomes were analyzed and compared to each 
other and to vaccine reference strains. PubMLST, a database hosted by the University of Oxford, 
was used to perform multi-locus sequence typing (MLST) and to determine alleles of genes that 
encode for pertussis toxin subunit 1 (ptxA), the pertussis toxin promotor (ptxP, pertactin (prn), 
and fimbriae serotype 3 (fim3), which are common components in acellular pertussis vaccines. 
Protein variants were then determined by comparing the protein sequences of PtxA, Prn, and 
Fim3 to known references using NCBI BLAST. Data gathered from PubMLST and protein 
alignments support other studies that indicate B. pertussis may be evolving to evade pertussis 
vaccines. Notably, all of the 14 strains analyzed in this paper carry a ptxP3 allele whereas 
vaccine reference strains such as Tohama 1 and C393 carry a ptxP1 allele. The other genes 
analyzed, ptxA, prn, and fim3, also showed divergence from the allele types of Tohama 1 and 
C393. This project builds on information gathered from previous studies and contributes to the 
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I. Introduction  
I-a Problem overview  
Pertussis, also known as whooping cough, is a contagious respiratory disease that is caused 
primarily by the bacterium Bordetella pertussis. Pertussis was first mentioned in literature in 
England during the mid-sixteenth century and the first epidemic was reported in Paris in 1578 (1, 
2) The name pertussis, meaning intense cough in Latin, was given to the illness in the late 
seventeenth century (2). B. pertussis was first isolated in 1906 by French scientists Bordet and 
Gengou (3). Pertussis outbreaks were a major cause of death, especially for young children, prior 
to the development of vaccines (4). After the introduction of pertussis vaccines in the 1940s, the 
number of cases and deaths from pertussis was reduced by around 90% (5). However, despite 
successful vaccination programs and high vaccination coverage, B. pertussis was never 
eradicated and continues to infect both vaccinated and unvaccinated people. Pertussis is one of 
the most poorly controlled vaccine-preventable diseases in the United States and around the 
globe. Recently there has been an increased number of reported pertussis cases in the United 
States (6). There are several proposed causes of this resurgence which include genetic evolution 
of B. pertussis, increased awareness of the disease, newer laboratory diagnostic techniques, and 
the switch from a whole-cellular vaccine to an acellular vaccine (7). 
 
 Fortunately, just as B. pertussis is evolving, so is our arsenal of technologies used to research 
and combat the bacteria. The emerging field of bioinformatics, which combines biology, 
computer science, and mathematics, is one way that researchers are using technology to study B. 
pertussis. The ability to sequence whole genomes quickly and affordably with next-generation 
sequencing (NGS) has greatly increased our knowledge about the bacteria. NGS and 
bioinformatics can be used to assemble, annotate, and compare genomes of various emerging 
strains of B. pertussis (8). In order to perform a bioinformatics analysis focused on molecular 
epidemiology it is important to understand the bacterium and illness it causes.  
 
The overall purpose of this project was to utilize NGS data and bioinformatics to analyze several 




One specific goal of this project is to perform a comparative bioinformatics analysis on recent 
Virginia B. pertussis isolates in order to assess the genomic variation. Another specific goal of 
this project is to build on information gathered from previous studies in an attempt to better 
understand the B. pertussis genome.  
 
I-b The culprit, Bordetella pertussis  
I-b-i Structure and virulence factors 
B. pertussis is a small, aerobic gram-negative bacterial pathogen that infects only humans. Gram-
negative bacteria have a lipopolysaccharide (LPS) layer that activates the immune response of 
their host (9). B. pertussis genomes contain mobile IS481 insertion elements (24). IS481 are 
mobile genetic elements that are thought to play a role in rearrangements and deletions by 
homologous recombination in the B. pertussis genome (24). B. pertussis produces many 
virulence factors, molecules produced by a bacterial pathogen that increase the bacteria’s ability 
to infect hosts and cause disease. This study will focus on the genes that encode for pertussis 
toxin (Ptx), Fimbriae (Fim), and pertactin (Prn), which are  protein components used in aP 
vaccines.  
 
Pertussis toxin (Ptx) is an exotoxin that utilizes a type IV secretion system (10). This secretion 
system is encoded by the ptl genes and transports Ptx across the bacterial outermembrane (11). 
Ptx is the cause of leukocytosis and lymphocytosis and is a potential cause of death from 
pertussis(9). The pertussis toxin promoter (ptxP) and pertussis toxin subunit 1 (ptxA) will be 
analyzed in this study. Fim is another virulence factor of B. pertussis which are found on the 
surface of the bacteria and are thought to function as adhesion factors (12, 13). Fimbria type 3 
(fim3) will be analyzed in this study because it encodes for Fim3, a component in aP vaccines 
(12).  Prn is a large protein, ~70kDa, that is used in aP vaccines. Interestingly, most current 
circulating strains do not express Prn indicating that it may not be essential to the pathogenesis of 
current strains (10). These virulence factors, along with other key virulence factors that will not 










The virulence factors shown above are what help B. pertussis infect a host and cause disease. 
Protection from infection by  B. pertussis depends on protective antibodies against bacterial 
proteins, including these virulence factors (6).  
 
I-b-ii Transmission and pathogenesis  
B. pertussis only infects humans and is transmitted by respiratory droplets from the coughing or 
sneezing of an infected person, making it very contagious (13). A single infected person can spread 
the disease to as many as 17 other individuals in unprotected populations (14–16).  Young children, 
especially infants under one year old, are particularly at risk to contract pertussis. Infants not only 
make up the highest percentage of pertussis cases, but are also much more likely to die from 
complications of the disease (1).  Recently, the rate of pertussis cases among adolescents and adults 
has shown to be increasing (6). While the mortality rates among adolescents and adults remains 




pertussis cases in infants can be attributed to transmission from an older family member such as a 
sibling, parent, or grandparent (9, 17, 18)  
 
The entire mechanism of pathogenesis of B. pertussis to humans is not yet clear.  The infection 
process begins in the respiratory tract where B. pertussis attaches to the cilia of epithelial cells 
(19).  Once attached to the epithelial cells B. pertussis produces toxins that paralyze cilia and 
inflame the respiratory tract. This inhibits the expulsion of pulmonary secretions which can lead 
to pulmonary hypertension(20, 21). The antigens created by pertussis seem to assist in the 
bacterial resistance to the host immune defense. A diagram of the mechanisms of pathogenesis of 
B. pertussis can be seen below in Figure 2.  
  
 
Figure 2. Pathogenesis of B. pertussis https://www.my-
pharm.ac.jp/~yishibas/research/Pertussis1.jpg The process begins with the 






I-c Symptoms, diagnosis, and prevention  
I-c-i Symptoms  
Once B. pertussis enters a viable human host the average incubation period ranges from 7-10 
days (6). In unimmunized children, the disease is described by three different stages—the 
catarrhal stage, the paroxysmal stage, and the convalescent stage. During the catarrhal stage, 
which usually last 1-2 weeks, symptoms can include a mild cough, sneezing, nasal congestion, 
and a mild sore throat (6). Pertussis is often over looked as a cause for these symptoms because 
they are similar to the symptoms of a common cold or other infections (9). This is unfortunate 
because the bacterium is very contagious during this catarrhal stage (6). 
 
The next stage that occurs is the paroxysmal stage. A defining symptom of this phase is the onset 
of a series of repetitive violent coughs, or paroxysms, in an attempt to clear mucus. After the 
paroxysm, the patient often inhales deeply then lets out a high-pitched whoop (6). This whoop is 
a defining characteristic of whooping cough. That is why the disease is usually identifiable as 
pertussis during this stage. The paroxysms are often more frequent and severe at night and are 
often followed by vomiting (9). The duration of this stage can last anywhere from 1-6 weeks.  
 
The final stage of the disease is convalescent stage. This stage can last for as little as a week to 
over several months. During this stage the severity and frequency of the paroxysms are gradually 
slowed until they stop. However, if the patient contracts a viral respiratory infection, the 
paroxysms often return (6). An image depicting the timeline of a pertussis infection can be seen 
below in Figure 3. These stages are typical in unimmunized children, but they can also occur in 
unprotected or partially protected adolescents and adults. However, the symptoms of the disease 
in adolescents and adults vary greatly between individuals, sometimes patients are asymptomatic 
(6). This can be dangerous as an asymptomatic adult can transmit the disease to an infant without 









There are a number of complications associated with a B. pertussis infection. Secondary bacterial 
pneumonia is not only the most common complication, but also the complication responsible for 
most pertussis-related deaths (6).  The paroxysm coughing associated with whooping cough can 
also cause seizures and other neurological complications due to a reduced oxygen supply to the 
brain. Other complications include but are not limited to dehydration, hernias, difficulty sleeping, 
and rib fracture (6). 
 
I-c-ii Diagnosis  
Pertussis is often hard to diagnosis because its early symptoms are similar to other common 
respiratory illnesses like the common cold. Because healthcare providers often fail to diagnose 
effectively, it is believed that pertussis is a greater burden to society than the statistics reflect 
(22). One study conducted on 61 pertussis patients concluded that pertussis was initially 






Pertussis can be diagnosed in several ways. The first indictor that might make a clinician test for 
pertussis is the paroxysmal cough that is unique to pertussis. However, patients sometimes do not 
cough during a short clinical visit therefore this can be missed by a patient’s healthcare provider 
(22). If a clinician suspects that a patient’s symptoms are due to pertussis, culture, polymerase 
chain reaction (PCR), and serology are the three main techniques used to tests patients and 
confirm a diagnosis. 
 
One way to test for pertussis is with PCR. One advantage of PCR is that it takes much less time 
than a culture. However, PCR tests are only effective in the beginning of the illness as the 
bacterial DNA diminishes after the first few weeks of the cough onset (6). Some PCR tests are 
very sensitive which can lead to a higher rate of false-positive results than with culture (6). 
Serological tests are another diagnostic tool that are useful after the patient has had the cough for 
several weeks. The CDC and FDA have developed serological assays that have been successful 
in diagnosing pertussis (6). 
 
A third way pertussis can be diagnosed is through culture. The culture is usually obtained from 
the nasopharynx. Cultures are more likely to be positive in the first stages of the disease (6). 
Cultures can take up to two weeks to give a definitive diagnosis (6). This means that sometimes 
the results of the culture are received too late to be useful to the patient (6).  
 
The usefulness of each test depends on several factors such as how long the patient has had a 
cough, the age of the patient, and the history of pertussis cases in the area where the patient lives 
(6) However, culture has distinct advantages over the other methods. While culturing the bacteria 
may be more difficult and time consuming than PCR or serological tests, it is essential for 
comparative genomics.  It is only through culturing that circulating strains can be isolated and 
sequenced for analysis. A graphical depiction of which diagnostic test should be used in relation 






 Figure 4. Figure illustrating optimal timeframe for the three laboratory pertussis diagnosis 
techniqueshttps://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html 
This figure shows the optimal test to use in relation to the number of weeks the patient has had a 
cough.   
 
I-c-iii Prevention  
A whole-cell pertussis vaccine consisting of a suspension of inactivated B. pertussis was 
developed in the 1930s. In the 1940s, the vaccine was combined with diphtheria and tetanus 
toxoids to create a multi-purpose vaccine know as DTP (6). It is estimated that this vaccine 
reduced the number of pertussis cases by around 90% (5). However, this vaccine had several 
short-term side effects such as fever and/or pain, swelling, and redness at the injection site (6). 
These effects caused some people to believe the vaccine was unnecessarily reactogenic. This 
safety concern lead to the development and implementation of less reactogenic acellular vaccine 
in the 1990s (6).   
 
The acellular vaccine for infants introduced in the 1990s, known as DTaP, consists of proteins 
instead of a whole-inactivated cell. In 2005, an acellular pertussis, diphtheria, and tetanus 
vaccine known as Tdap which was designed for adolescents and adults became available (9). 




While these acellular vaccines are less reactogenic, it is widely believed that the switch from a 
whole-cell to an acellular vaccine is at least partially responsible for the increasing number of 
pertussis cases (6).  An image supporting this hypothesis can be seen below in Figure 5. Some 
research suggests the acellular vaccine is not only less effective, but also effective for a shorter 
amount of time than its whole-cell counterparts (6). 
 
 Figure 5. Graph depicting U.S. pertussis cases in relation to time. The introduction date of 
the various vaccines is depicted on the graph. A sharp drop in pertusssis cases is seen with the 
introduction of the DTP. The recent resurgence is seen in the inlay.  
https://www.cdc.gov/pertussis/images/incidence-graph.png 
 
I-d Public policy, cultural dynamics and stakeholders  
I-d-i Public policy and cultural dynamics 
Public policy and cultural dynamics are intertwined in the case of pertussis. As seen in the previous 
section, vaccination policies are often shaped by public concern of vaccination risk (6). The current 
U.S. vaccination strategy was developed in response to the public’s distrust of the whole-cellular 
vaccine (24). However, some countries that did not experience similar public outrage still 




compulsory school vaccinations. This means that unless a child has a valid medical or religious 
reason not to be vaccinated, that child must be vaccinated in order to attend school (24). 
 
These mandates have allowed the United States to achieve vaccination coverage of over 95% (37). 
This high-vaccination coverage is important in maintaining herd immunity in the United States. 
The concept of herd immunity states that the higher the vaccination coverage of a population then 
the less likely an outbreak is to occur. For this reason, when parents decide not to vaccinate their 
own children, they are not only jeopardizing their children’s health, but also may be jeopardizing 
the health of other children as well. The concept of herd immunity is illustrated in Figure 6 below. 
 











I-d-ii Stakeholders analysis  
There are many government and private stakeholders involved in developing and improving the 
United States pertussis vaccine. Stakeholders are involved in a dynamic relationship in order to 
create vaccines that are effective, safe, and accessible. One group of stakeholders is the general 
public. The public plays a crucial role in vaccine development by participating in trials (25). 
Public opinion and concern also plays a major role in developing policy (24). 
 
Another stakeholder in vaccine development is the media. Media plays a large role in shaping 
public opinion. It is important for the media to make sure they relay accurate information to the 
general public. If the media provides the public with inaccurate information, it can negatively 
impact people who trust media as their source of vaccination information (25).  
 
A third group of stakeholders is vaccine manufacturers. Creating a vaccine is a very expensive 
process with a high chance for failure (25). However, vaccine manufacturing can be a very 
lucrative business. Top vaccine manufacturers such as Merk and Pfizer generate billions of 
dollars in revenue each year (25). It is the ethical responsibility of these vaccine manufacturers to 
develop the safest, and most effective vaccine possible for the public.  
  
Health professionals also play an important role in pertussis treatment and vaccine development. 
Doctors play a critical role in conveying the importance of vaccinations to their patients and also 
must be trained to correctly diagnose the disease in their patients (24). Medical researchers also 
play an important role in leading research for vaccine development.  
 
Another group of stakeholders is government agencies. Government agencies like the FDA make 
sure vaccine manufacturers are creating safe vaccines. Agencies such as the CDC play an 
important role in tracking pertussis epidemics as well as conducting important research to 
understand the disease (24). The government also spends billions of dollars treating vaccine-
preventable diseases each year (26). This tax burden could be reduced by the development of 





While some stakeholders are excluded from this analysis, the final stakeholder mentioned in this 
analysis is academia.  Academia plays an important role in conducting research as well as 
developing future leaders in various other sectors of stakeholders (25). It is important to note that 
one person may play the role of many different stakeholders. An example of this would be a 
physician hat may play a role as a clinician, researcher, volunteer, and a parent.  
  
II- Objectives  
II-a Contribute to the growing knowledge of the evolution of the B. pertussis genome.  
The goal of this project is to contribute to the growing knowledge of the B. pertussis genome.  
 
II-a-i Perform DNA isolation and sequencing of two Va clinical isolates. 
DNA purification was performed on two VA clinical isolates at the University of Virginia's 
Hewlett Lab. Sequencing was then performed at the Delaware Biotechnology Institute at the 
University of Delaware.  These strains contribute to the growing number of B. pertussis whole-
genome sequences.  
 
II-a-ii Perform bioinformatics analysis on new strains and twelve previously sequenced VA 
clinical isolates. 
To understand the genomic and proteomic content of the two new strains and twelve previously 
sequenced VA clinical isolates, a bioinformatics analysis was performed. This included an 
alignment of the protein sequences using progressiveMauve, the creation of a structural 
similarity tree using Maximum Likelihood for Gene Order Analysis, Multi-Locus Sequence 








III- Materials and methods  
III-a Isolate Collection  
 The isolates used in this study were collected by the Virginia Division of Consolidated 
Laboratory Services (DCLS) from 2001-2015 (27). The isolates are accompanied with patient 
vaccination status and other clinico-epidemiological data from the Virginia Department of 
Health (VDH) (27).  Isolates accompanied with this information are rare due to a shift from 
bacterial culture to PCR as the preferred diagnostic method in some regions (27).  
 
III-b DNA purification, sequencing and assembly  
III-b-i DNA purification. 
To contribute to the increasing number of B. pertussis whole genome sequences, two new VA 
clinical isolates from UVA's repository were purified and sequenced. DNA was purified using 
the Wizard® Genomic DNA Purification Kit for Isolation of Genomic DNA from Gram 
Negative Bacteria with modifications. The modifications were made by Dr. Laure Gonyar to 
optimize genomic based on previous experience. The protocol from Wizard® can be seen below.  
 
The cells were pelleted by centrifuging 1ml of overnight culture for two minutes at 16,000 x g 
and then discarding the supernatant. The first step in the lysing procedure was to add of 600 µl 
Nuclei Lysis solution and gently mix by pipetting. The mixture was then incubated for 5 minutes 
at 80°C and cooled to room temperature. Next 3µl of RNase Solution was added, incubated at 
37°C for 45–60 minutes, then cooled to room temperature. Proteins precipitation was done by 
adding 200µl of Protein Precipitation Solution, vortexing for 30 seconds, incubating on ice for 1 
hour, and centrifuging at 16,000 x g for 10 minutes.  
 
The first step in DNA precipitation and rehydration was to transfer the supernatant to a clean 
tube with 600µl of room temperature isopropanol and mix. The solution was then centrifuged for 
20 minutes at 16,000 x g and the supernatant was decanted. We then added 600µl of room 
temperature 70% ethanol, mixed, and centrifuged for 5 minutes at 16,000 x g. The ethanol was 




100µl of Rehydration Solution overnight at overnight at 4°C.  
 
After purification, the purity of the DNA from each sample was measured using a nanodrop 




III-b-ii Sequencing and assembly 
Sequencing was performed by the Delaware Biotechnology Institute at the University of 
Delaware using Pacific Bioscience's PacBio RSII system. The RSII system utilizes Single-
Molecule, Real Time (SMRT) technology (28). SMRT technology works by immobilizing DNA 
polymerase and template at the bottom of a well and utilizing phospholinked nucleotides to view 
a DNA strand as it is produced by DNA polymerase (28).  First, genomic DNA was used to 
create SMRTbell template libraries according to PacBio's standard 20-kb library (29). One 
SMRT cell was used for each strain. Next, sequencing was performed on the PacBio RSII 
sequencer. Finally, the genomes were assembled de novo using the Hierarchical Genome 
Assembly Process (HGAP)(28). The PacBio RSII sequencer is particularly useful for sequencing 
of B. pertussis because it utilizes long-reads which can improve the accuracy of sequencing 
genomes with mobile elements and structural rearrangements that are characteristic of the B. 
pertussis genome  
 
III-c Genome annotation and annotation comparison.  
III-c-i Genome annotation 
Rapid annotation using subsystem technology (RAST) was used to annotate the genomes (30). 
Genomes were uploaded to RAST and then annotated according to the parameters shown in 






 Figure 7. RAST settings used to annotate the genomes.  
    http://rast.nmpdr.org/ 
 
 After sequences were annotated, they were submitted to GenBank. It should be mentioned that 
the sequences currently on GenBank have been reannotated with NCBI's Prokaryotic Genome 
Annotation Pipeline (PGAP),  a service available for GenBank submitters. NCBI's annotation 
pipeline uses several NCBI databases and is not available for public download (31).   
 
 
III-c-ii Genome annotation comparison 
To compare the annotations of the 12 previously sequenced VA clinical isolates, 
progressiveMauve was used to align the sequences. ProgressiveMauve is a free downloadable 
tool that creates positional homology alignments and excels in aligning rearranged genomes (32). 
To do this, the 12 previously sequenced VA isolates were downloaded from GenBank. The 
sequences can be found by searching NCBI's BioProject database for accession number 
PRJNA321467. Once the GenBank sequences were downloaded, they were input into 
progressiveMauve along with the GenBank sequence for reference strains Tohama I E4786 and 
Chinese reference strains (CS) C393 for alignment using default parameters. Tohama I and C393 
were chosen because they are some of the strains that are used to derive the protein components 





III-d Structural similarity tree construction 
III-d-i Permutations output file and data formatting.  
To view the structural similarity of the sequences a permutations output file was first generated 
from the progressiveMauve alignment by clicking Tools → Export→ Export permutations. Next, 
Maximum Likelihood for Gene Order Analysis (MLGO) was performed. To do this, the file was 
reformatted using the search and replace tool in Visual Studio Code to switch commas to spaces 
and add name labels. The original progressiveMauve file and the edited MLGO input format file 
can be accessed in the supplemental materials section.  
 
III-d-ii Submission of job to MLGO and creation of tree using R  
Next, the MLGO input format file was uploaded into the input data section of MLGO web server 
hosted at www.geneorder.org (34).  The interference target was selected to be phylogenetic tree 
reconstruction. The progressiveMauve guide tree was then input under the small phylogeny 
problem only section.  
 
To visualize the MLGO output tree, the .tree file was downloaded from the zip file. An R script, 
shown below, that utilizes the tidyverse CRAN package and Bioconductor ggtree package was 
then used to visualize the tree (35).  
 
 







III-e MLST and virulence factor allele typing  
III-e-i Overview of BIGSDB and PubMLST 
To compare our sequences to other sequences MLST was performed using www.pubmlst.org 
(PubMLST) Bordetella spp. database (36). PubMLST is a site hosted by The Department of 
Zoology at the University of Oxford with funding from The Welcome Trust (36).  PubMLST is 
powered by the BIGSDB software platform, which is an open source, online-hosted system that 
links phenotype and sequence data from whole genomes to bacterial specimens (37). PubMLST's 
Bordetella database uses two linked databases. The Sequence definitions database contains allele 
sequences and MLST profile definitions and the Isolate database contains epidemiological 
information (36).   
 
III-e-ii MLST and sequence typing 
MLST and strain typing was performed based on seven housekeeping genes described previously 
(38). The seven housekeeping genes used in the Bordetella MLST are adk, fumC, glyA, tyrB, icd, 
pepA, and pgm. To perform MLST and strain typing, PubMLST was accessed and the following 
process was used: Databases → Bordetella spp. → Sequence and profile definitions → Sequence 
query → select MLST scheme → choose strain FASTA file → Submit. After the FASTA file 
was submitted, the screen returned the allele types for each of the seven housekeeping genes. 
The combination of these alleles was used to determine the sequence type (ST). The MLST 
profile and ST was recorded for each isolate.  
 
III-e-iii Virulence factor allele typing  
To understand how virulence factor genes may be evolving due vaccine selection pressure, 
several virulence factors commonly used in molecular typing were analyzed (39).  The loci 
analyzed were prn, ptxS1 (ptxA), ptxP, and fim3 (fimH). These loci were chosen because they 
encode antigens commonly used in aP vaccines and may shed light onto selective pressures 
caused by the vaccine (40). To perform molecular typing, PubMLST was accessed and the 
following process was used: Databases → Bordetella spp. → Sequence and profile definitions → 
Sequence query → select All loci → choose strain FASTA file → Submit. Once the job was 






After the alleles were determined from the nucleotide fasta sequences, the genbank (.gbk) files 
were used to determine the protein variant of the loci. This was done because there are more 
nucleotide alleles than protein variants due to nucleotide mutations that do not change the protein 
sequence (41). To determine protein variants, the protein sequences of Prn, PtxS1, and Fim3 
were downloaded from the VA .gbk files then compared to known sequences for each protein 
variant that were described in previous studies using ClustalOmega (42, 43). The information 
from this molecular typing analysis was then compared to similar studies done in the United 
States and globally.  
 
IV Results and Discussion 
IV-a ProgressiveMauve whole-genome alignment  
The annotation and alignment of the genomes indicated that there was little variation in the 
genomic content of the Va isolates between the genomes. However, while all the genomes have 
similar genetic content, there is significant genomic rearrangement between the Va clinical 
isolates. ProgressiveMuave illustrates rearrangements with locally colinear blocks (LCBs) that 
represent regions in different genomes that occur in the same order and orientation (32).  Each 
row in the alignment represents a strain and the LCBs are illustrated by blocks of the color in 
different genomes (32). The lines that connect the LCBs illustrate the relative position of an LCB 
in one genome to the same LCB in another genome (32).  The progressiveMauve alignment of 
temporarily different Va clinical strains along with Tohama 1 and C393, as shown in figure 9, 
indicates significant rearrangement of the genomes shown by the pronounced crisscrossing of the 
LCB connecting lines. Recent studies using similar methods have shown that the majority of  
these rearrangements are caused by large inversions at the replication origin or terminus that are 




Figure 9. Figure showing progressiveMauve alignment 5 VA strains and vaccine reference 
strains based of local collinear blocks (LCBs). The vaccine references trains, C393 and 
Tohama 1, are the first two strains and VA-09, VA-52, VA-145, VA-94, VA-150, and VA-190 
follow. The LCBs in the different genomes are indicated by different colors. The lines 
connecting the LCBs indicated the relative position of the LCBs in the different genomes. These 
connecting lines show large internal inversions within the strains. 
 
IV-b Cladogram based on LCB order 
The progressiveMauve permutations file which contains LCB orders for each genome was input 
into MLGO to create a tree file. This tree file was then downloaded, and an R script was used to 






Figure 10. Cladogram based on LCB order of VA clinical Isolates and Tohama / C393  
vaccine reference strains.  
 
In figure 10 above, the length of the branches indicate the magnitude of rearrangements between 
the strains (44).  The noticeably longer branch of Tohama 1and C393 indicates that the Va 
clinical isolates have undergone significant rearrangements compared to vaccine reference 
strains (44). This indicates that the structural arrangement of Tohama 1 and C393, which are 
commonly used reference strains used to produce vaccines, may not be representative of 
circulating B. pertussis strains in Virginia (45).   
 
 
IV-c Multi-Locus Sequence Typing (MLST)  
MLST was performed using  www.pubmlst.com according the allele sequences of seven 
housekeeping genes (adk, fumC, glyA, tyrB, icd, pepA and pgm) that were described in 
Diavatopoulos et al 2005 (38). All the 14 Va strains in this this study except for VA-190 and 
VA-198 were determined to be sequence type (ST) 2.  
 




the late 1990s as opposed to ST1, the sequence type of reference strains such as Tohama 1 (46). 
This change in ST is characterized by a change in the tyrB allele from 1 to 3 (47).  
 
VA-190 and VA-198 were determined to ST83. This is a new strain type that was entered into 
the pubmlst database in February of 2018. This strain type profile is the same as ST2 except for a 
change in icd allele from 1 to 11. The ST1, ST2, and ST83 and the current number of isolates in 
the pubmlst database associated with each sequence type can be seen below in figure 11.  
 
 
Figure 11. Figure showing the allele numbers, and the current number of isolates in the 
pubmlst isolate database for ST1, ST2, and ST83  
 
Some literature suggest the emergence of ST2 as the dominate sequence may be associated with 
the introduction of aP vaccines in the 1990s (48). Most sequences in this study were ST2, which 
are consistent with circulating strains mentioned in other studies (46). However, two of the 
strains were ST83, which is a new designation that has not been discussed in published literature. 
While there are 24 other isolates in PubMLST's database with ST 83, only one other isolate has a 
date associated with its isolation, 2010. This is only a few years prior to when the Va ST 83 
strains were isolated, 2013.    
 
IV-d Virulence factor allele typing  




promoter (ptxP), and fimbriae 3 (fim3) were analyzed. These genes were analyzed because they 
code for surface proteins, their products are often used as components in aP vaccines, and 
because they have shown divergence from vaccine reference strains (46, 49).  Strain variation 
has been shown to alter vaccine efficacy in murine models (50).  The allele types, derived from 
PubMLST, of the selected virulence factors can be seen in table 1. 
 
Table 1. PubMLST allele designations and predicted protein variants. PubMLST nucleotide 
allele designations may not be the same as designations commonly used in B. pertussis studies. 
The highlighted strains are the strains sequenced in this study and the vaccine reference strains 
are bold. Predicted protein variants for Prn, PtxA, and FimH were found by aligning proteins 
with known reference alleles previously described (51) 
Strain  prna Prnb ptxAc,d PtxA ptxP fimHe,f FimH  Year PFGE  
VA-09 9 2 1 1 3 3 2 2001 vabpx002 
VA-010 9 2 1 1 3 3 2 2001 vabpx001 
VA-15 9 2 1 1 3 3 2 2001 vabpx001 
VA-18 9 2 1 1 3 3 2 2001 vabpx002 
VA-52 9 2 1 1 3 3 2 2005 vabpx002 
VA-62 9 2 1 1 3 3 2 2005 vabpx008 
VA-94 9 2 1 1 3 1 1 2008 vabpx007 
VA-145 9 2 1 1 3 3 2 2010 vabpx002 
VA-150 NULL  - 1 1 3 1 1 2010 vabpx023 
VA-162 NULL  - 1 1 3 1 1 2011 vabpx007 
VA-175 NULL  - 1 1 3 1 1 2012 vabpx018 
VA-190 NULL  - 1 1 3 3 2 2013 vabpx045 
VA-194 NULL  - 1 1 3 1 1 2012 vabpx008 
VA-198 NULL  - 1 1 3 3 2 2013 vabpx030 
Tohama 1 1 1 4 2 1 1 1 1954 CDC232 
C393 1 1 4 2 1 1 1 1951 CDC052 
a  NULL in this column means PubMLST did not return any values for prn  
b  - in this column indicates functional pertactin was not expressed  
c ptxA is also designated ptxS1 
d alignment of Tohama 1 and C393 ptxA allele with a reference alleles showed PubMLST’s 
ptxA4 designation is the same sequence as ptxA2 that has been characterized in literature (51). 
e fimH is also designated fim3 
f alignment of fimH3 alleles with reference alleles showed that PubMLST’s fimH3 designation is 





IV-d-i Pertactin  
Pertactin is one of the most variable genes in the B. pertussis genome (52). Strains used to derive 
aP vaccines, such as Tohama 1, contain the  prn1 allele which encodes for the Prn1 antigenic 
variant (12). Today, Prn2 strains dominate most vaccinated populations worldwide (10). Prn 
deficient strains are becoming increasingly common among vaccinated populations (53).  The 
ability of B. pertussis to infect without one if its presumed critical virulence factors suggests that 
the bacterium may be evolving to evade the immunity produced by the vaccine (33).  
 
The PubMLST results indicate that eight of the strains are prn9.  However, when the protein 
sequences of these strains were compared to known references with ClustalOmega, all prn9 
strains were determined to be Prn2. This may be because most variation of prn alleles occurs in 
repeat motifs that do not alter the amino acid sequence (53).  
 
PubMLST indicated that six of the strains were prn deficient. A manual check of the .gbk 
sequences gave insight into potential reasons why these strains did not express Prn. A table 
showing the notes for pertactin in the .gbk files for the strains can be seen below in table 2.  
 
Table 2. Table showing notes for pertactin in the .gbk files of pertactin deficient strains. 
Notes were created during the PGAP and derived by automated computational analysis using 
gene prediction method: Protein Homology. 
Strain  Start  Stoop Note  
VA150 1079795 1082542 internal stop; 
VA162 3926910 3928184 Unknown disruption 
  3928248 3929657 Unknown disruption  
VA175 1079802 1081415 
incomplete; partial in the middle of a contig; missing 
stop; 
  1082462 1083598 
incomplete; partial in the middle of a contig; missing 
start; 
VA190  3322295 3325040 frameshifted; 
VA194 1233042 1235549 
incomplete; partial in the middle of a contig; missing 
start; 





The Prn analysis of our strains demonstrated that the Prn1 component used in most acellular 
vaccines is not representative of the Prn protein variant of strains circulating in Va. The Va 
strains in this study either exhibited Prn2 or were Prn deficient.   
 
IV-d-ii Pertussis toxin subunit 1 (ptxA)  
Pertussis toxin (PT) is a complex toxin made up of multiple subunits (one active subunit and five 
binding subunits) (11). Pertussis toxin subunit 1 (ptxA), also designated ptxS1, is the first gene in 
the PT operon and where the enzymatic activity of PT resides (12, 11). All 14 of the Va strains 
exhibited a ptxA1 allele. This is consistent with other studies that claim around 90% of global 
circulating strains harbor a ptxA1 allele (64,). This is in contrast to vaccine reference strain 
Tohama 1 harbors a ptxA2 allele which encodes for the PtxA2 (55). PtxA1 is thought to have 
replaced PtxA2 as the predominant variant after the introduction of whole-cell whooping cough 
vaccines (10). The rapid replacement of PtxA2 with PtxA1 as the dominant allele indicates that 
the bacterium may be evolving to escape vaccine induced immunity and increase strain fitness 
(54). 
IV-d-iii Pertussis toxin promoter (ptxP) 
Unlike the other virulence factors studied in this analysis, ptxP has no protein product that is 
used to produce aP vaccines (56). However, ptxP regulates the expression of ptxA and certain 
ptxP alleles have been shown to significantly increase the expression of PT (51). Tohama 1 and 
other vaccine strains contain a ptxP1 allele (12).  All of the 14 Va strains exhibited a ptxP3 
allele. This is consistent with other studies that have found that since their detection in the 1990s, 
ptxP3 strains have increased in frequency and now represent up to 90% of circulating strains in 
some areas (41).In one study, PtxP3 was shown to increase expression of PT by a factor of 1.6 
relative to ptxP1 (51). This increased production of PT increases may give ptxP3 strains a 
selective advantage over ptxP1 strains which could explain the predominance of ptxP3 strains 
(57). It has been hypothesized that the increased production of PT may increase the severity of 
the disease leading to higher hospital rates and subsequently a higher reported number of ptxP3 
strains (57).  
 




Fimbriae serotype 3 (fim3), also fimH, is another gene that encodes Fim3 which is a component 
of many acellular vaccines(58, 59). Fim3-1, fimH1, and fim3A are all used in different studies to 
refer the same nucleotide sequence for a fim allele(39, 58). The PubMLST typing results for fim3 
(fimH) can be seen in table 1.  
 
It is important to note that because of the way PubMLST assigns allele designations, the 
PubMLST allele type may not be the same designation as the allele type used in current 
literature. An example of this is seen in table 1. While PubMLST calls fimH3 for VA-09, VA10, 
VA15, VA-15, VA-18, VA-52, VA-62, VA-145, VA-190, and VA-198, there nucleotide 
sequence is the same as fim3-2 (fim3B) that is mentioned in literature (58). This is because in the 
literature there is a fim3-1* (fim3A*) designation that encodes for the same protein as fim3-1 but 
has a silent polymorphism at that changes C to T at position 29 of the nucleotide sequence (58).  
 
Tohama 1 contains a fim3-1 allele. Our results are consistent with other studies that show a 
correlation of increased cases and the emergence of fim3-2 from the early 2000s until around 
2010 (12). However, also consistent with other studies, there seems to be an unexplained 
reemergence of the fim3-1 allele around 2010 (12).  
 
V. Conclusions and future work  
Pertussis is the most poorly controlled vaccine-preventable disease, and the number of cases has 
been on the rise since the 1990s. This study investigated bacterial evolution as a possible reason 
for this resurgence. In this study, a total of fourteen VA clinical B. pertussis isolates were 
compared to each other and to vaccine reference strains Tohama 1 (E4786) and CS (C393). An 
analysis of gene clustering using the order and orientation of homologous sequence blocks 
showed that the vaccine strain and other strains with the fimH1 group together.  
Reference vaccine strains used to produce acellular vaccines are not representative of circulating 
strains. For this reason, several genes that encode for vaccine components were also analyzed. 
The analysis showed that Virginia B. pertussis strains have prn, ptxA, ptxP, and fim3 allele types 
that are not only divergent from vaccine strain allele types but also consistent with the allele 





While each strain had PFGE data associated with it, this data was not incorporated in this 
analysis due to troubles with interlaboratory comparison of PFGE results. Originally, I wanted to 
do an unbiased SNP search to see if the frequency of SNPs in virulence genes in relation to other 
functional categories. Factors that I believe limited my success in this were these: 1. Lack of 
funds for proprietary software (i.e. CLC genomics workbench),  2. inexperience with the Linux 
operating system, since many programs are in Linux. , and 3. Many programs are not designed to 
handle long-reads (i.e. Geneious).   
 
There is a significant amount of future work to be done with these and other B. pertussis strains. 
One thing that may be useful is to develop a standardized pipeline for sequencing, annotating, 
and characterization of B. pertussis isolates. This will improve the ability to study strains from 
different temporal periods and geographical regions to better understand the evolution of the 
bacterium.  
 
Whole-genome multi-locus sequence typing is one future research avenue that is being 
developed by the CDC. While this pipeline is still in preliminary phases, and there is no 
published work on it, the CDC is investigating a whole-genome multi-locus sequence typing 
scheme that looks at around 3600 targets instead the 5 that are currently investigated. This would 
provide a better understanding of evolution across the entire genome and not just a select few 
virulence factors.  
 
Another future research avenue is studying potential new vaccine antigens. The evidence that 
most recent circulating strains are Prn deficient indicates that some of  the current aP vaccine 
antigens may not be essential. This means that novel vaccine antigens should be explored to 
potentially improve the vaccine. However, one caveat with developing a new vaccine is that the 
pertussis vaccine is currently a component diphtheria, tetanus, and pertussis (DTaP) vaccine. 
This means that changing the pertussis protein components would require the development of a 
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